Back to database

Cagrilintide

Also known as: NN9838

GLP-1 / Weight LossPhase 3 Clinical TrialsSubcutaneous

A long-acting amylin analog being developed in combination with semaglutide (CagriSema) for obesity and type 2 diabetes treatment.

Molecular Weight

~3950 Da

Half-Life

~7 days

Sequence

Long-acting amylin analog

Mechanism of Action

Activates amylin receptors in the brain to promote satiety, slow gastric emptying, and suppress glucagon secretion. Complementary pathway to GLP-1.

Dosing Protocol

Titrated from 0.25mg weekly up to 2.4mg weekly. Often combined with semaglutide.

Open peptide calculator
Reconstitution

Research-grade: 10mg vial + 2mL BAC water.

Storage

Refrigerate 2-8°C.

Side Effects
  • ●Nausea
  • ●Injection site reactions
  • ●Diarrhea
Key Research Findings
  • ●CagriSema combination: ~15.6% weight loss at 32 weeks
  • ●Additive effects with GLP-1 agonists on appetite suppression
  • ●Improved postprandial glucose control

Research Use Only

This information is provided for educational and research purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before using any research compounds.